Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Trial Profile

Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Lanifibranor (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jul 2018 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2019.
    • 26 Jul 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.
    • 20 Jun 2018 According to an Inventiva Pharma media release, first patient is expected to be enrolled in the third quarter of 2018 and topline results are expected beginning of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top